



Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors

Yezi Zhu · Susan L. Dalrymple · Ilsa Coleman · S. Lilly Zheng · Jianfeng Xu  · Jody E. Hooper · Emmanuel S. Antonarakis · Angelo M. De Marzo · Alan K. Meeker · Peter S. Nelson · William B. Isaacs · Samuel R. Denmeade · Jun Luo · W. Nathaniel Brennen  · John T. Isaacs 

Published online: 6 May 2021

© The Author(s), under exclusive licence to Springer Nature Limited 2021

Correction to: *Oncogene* (2020) **39**,6935–6949
<https://doi.org/10.1038/s41388-020-01479-6>
published online 28 September 2020

Unfortunately, an error occurred in Table 1. The corrected Table 1 is given below.

The original version was corrected.

Table 1 Phenotypic and growth characteristics of CWR22, CWR22-RH, LvCaP-2, LvCaP-2R, SkCaP-1, SkCaP-1R, LNCaP, and LN-95.

	CWR22	CWR22-RH	LvCaP-2	LvCaP-2R	SkCaP-1	SkCaP-1R	LNCaP	LN-95
RNAseq classification	AR+ PCa	AR+ PCa	AR+/NE+ PCa	AR+/NE+ PCa	AR+ PCa	AR+ PCa	AR+ PCa	AR+ PCa
Tissue of origin	Primary	CWR22	Liver Met	LvCaP-2	Skin Met	SkCaP-1	Lymph Node Met	LNCaP
Patient treatment history	None	ADT, Abi, Carboplatin, and Enza	ADT, Abi, Carboplatin, and Enza		ADT, Taxane, Abi, Carboplatin, Enza		Castration	
Histology	Poorly differentiated adenocarcinoma	Poorly differentiated adenocarcinoma	Poorly differentiated amphicrine carcinoma	Poorly differentiated amphicrine carcinoma	Poorly differentiated adenocarcinoma	Poorly differentiated adenocarcinoma	Poorly differentiated adenocarcinoma	Poorly differentiated adenocarcinoma
in vivo growth response to ADT	Yes	No	Yes	No	Yes	No	Yes	No
Xenograft doubling time	11 ± 3 days (Intact Host)	10 ± 2 days (Intact or Castrate Host)	10 ± 3 days (Intact host)	9 ± 2 days (Intact or castrate host)	14 ± 5 days (Intact host)	18 ± 4 days (Intact or castrate host)	12 ± 5 days (Intact); 26 ± 7 days (Castrate)	6 ± 3 days (Intact or castrate host)
AR	Homozygous GOF H878A mutation	Homozygous Double GOF H875Y & T878A mutation	Wild type + low- to-no V7	Wild type + V7	Wild type	Wild type + V7	Homozygous T878A GOF mutation	Homozygous T878A GOF mutation + V7
Normalized AR mRNA	4	11	52	256	4	388	17	30
Normalized AR protein	6	25	11	50	7	80	33	59
AR-FL/AR-V7 protein ratio	>100:1	>100:1	>100:1	6:1	>100:1	12:1	>100:1	8:1
TP53	Heterozygous LOF G154F mutation	Heterozygous LOF G154F mutation	LOF T211fs mutation	LOF T211fs mutation	Wild type	Wild type	Wild type	Wild type
PTEN	Wild Type	Heterozygous LOF T321fs mutation	LOH & Hemizygous Deleterious R130Q mutation	LOH & Hemizygous Deleterious R130Q mutation	Homozygous Deletion	Homozygous Deletion	LOH & Hemizygous p.K6fs Deleterious AA mutation	LOH & Hemizygous p.K6fs Deleterious AA mutation
ERG	No	No	No	No	Yes	Yes	No	No
c-Myc	>80%	>80%	>80%	>50%	>40%	>60%	>50%	>75%
Nkx3.1	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Ki67	72 ± 27%	83 ± 6%	80 ± 6^	75 ± 9%	45 ± 3%	39 ± 4%	47 ± 12%	82 ± 12%
PSA	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Serum PSA (ng/mL/g)	462 + 67 (Intact host)	249 ± 41 (Castrate host)	59 ± 11 (Intact host)	25 ± 6 (Castrate host)	284 ± 51 (Intact host)	44 ± 12 (Castrate host)	185 ± 34 (Intact host)	50 ± 10 (Castrate host)
PSMA	Yes	Yes	Focal	Focal	>50%	>50%	Yes	Yes

Table 1 (continued)

	CWR22	CWR22-RH	LvCaP-2	LvCaP-2R	SKCaP-1	SKCaP-1R	LNCaP	LNCaP-95
CK5	No	No	No	No	No	No	No	No
CK18	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
B-catenin	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type
RB	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type
ChgA	No	No	Yes	Yes	No	No	No	No
HoxB13	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
TP63	No	No	No	No	No	No	No	No
Sox2	No	No	No	No	No	No	No	No
BRCA2	Heterozygous LOF E984fs mutation	Heterozygous LOF E984fs mutation	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type
PIK3CA	Heterozygous Q546R mutation	Heterozygous Q546R mutation	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type
MSH2	Wild type	Wild type	Wild type	Wild type	Wild type	Wild type	MSI, homozygous deletion	MSI, Homozygous Deletion